Jump to Main Content

ASH HFFTP Awarded Institutions

University of California, San Francisco

"We are committed to training the next generation of non-malignant hematologists and honored to partner with ASH in this endeavor. The HFFTP at UCSF reflects our institution's unique strengths, mission, and values to advance health worldwide. UCSF's investments in genome engineering, biomedical and clinical big data, digital health, medical education, and health care disparities research in addition to basic, translational and clinical research provide the intellectual community and resources for HFFTP fellows to develop innovative, high-impact, and gratifying careers in hematology."

Gerald Hsu, PhD, ASH HFFTP Associate Program Director
Contact: [email protected]

"We are so thrilled to have been selected as one of the ASH HFFTP centers.  We plan to offer a breadth of educational experiences for fellows wishing to pursue training in non-malignant hematology as well as individualized research opportunities across multiple scientific domains."

Patricia A. Cornett, MD, ASH HFFTP Program Director
Contact: [email protected]


The UCSF HFFTP Track builds on institutional strengths with 5 integrated paths of concentration: genome engineering, medical education, biomedical informatics, health disparities, and traditional clinical or lab research. These paths feature areas of innovation at UCSF and UC Berkeley with pioneers in technologies for genome engineering and their application, investments in big data and the expertise to harness it, commitment to understanding the factors that drive health care disparities, and investigators that collectively receive the highest amount of NIH funding of any public institution. Each path includes distinct didactic and scholarly activities integrated with clinical and mentored research experiences.

Clinical training in laboratory and transfusion medicine, anticoagulation and thrombosis, pediatric hematology, and inpatient hematology consultation is complemented by multidisciplinary training in the west coast’s largest comprehensive center for sickle cell disease, the nation’s largest thalassemia program, a national hemophilia treatment center, a hereditary hemorrhagic telangiectasia center of excellence, and a birthmark and vascular anomalies clinic. With defined paths of concentration and clinical and research opportunities that capture the breadth of non-malignant hematology, our proposed HFFTP is designed for fellows to realize career aspirations and become thought leaders who advance the science, translation, and practice of hematology.